Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It is employed to manage high blood pressure and to treat heart failure, particularly after a myocardial infarction, in adult patients who need additional blood pressure control or have reduced left ventricular function.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this cardiovascular therapy, ensuring compliance with global quality standards.

Eplerenone is an aldosterone antagonist used in cardiovascular disease management.

Hypertension: lowers blood pressure by reducing sodium retention and fluid volume. Heart failure (post‑myocardial infarction): improves survival and reduces hospitalizations in patients with reduced left ventricular function. Left ventricular dysfunction after MI: helps attenuate adverse cardiac remodeling and supports ventricular function.

Eplerenone may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Diarrhea - Abdominal pain

Serious or Rare Side Effects: - Hyperkalemia (elevated blood potassium) - Acute kidney injury - Severe allergic reaction (anaphylaxis) - Gynecomastia (rare) - Hepatic dysfunction - Severe hypotension

Before initiating therapy, consider the following precautions.

Monitor serum potassium and renal function regularly. Avoid use in patients with existing hyperkalemia. Use caution in patients with moderate to severe renal impairment. Adjust dose in elderly patients or those with reduced hepatic function. Concomitant use with potassium‑sparing diuretics or supplements may increase risk of hyperkalemia. Store at below 25°C: keep in the original pack, protect from moisture.

Eplerenone can interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - ACE inhibitors or ARBs (risk of additive hyperkalemia) - Potassium supplements or potassium‑sparing diuretics - NSAIDs (may worsen renal function) - Cyclosporine (increased risk of hyperkalemia) - High‑dose thiazide diuretics (electrolyte disturbances)

Moderate Interactions (Monitor Closely): - Digoxin (altered serum levels) - Lithium (increased lithium toxicity) - CYP3A4 inhibitors (e.g., ketoconazole) may raise eplerenone levels - Antifungal agents (potential increase in potassium) - Certain antibiotics (e.g., trimethoprim) that affect potassium balance